“Cytotoxic therapy remains the backbone of treatment for many metastatic tumors, either alone or in combination with targeted therapies,” said Raj Malik, M.D., G1’s Chief Medical Officer. “But the high toxicity of these cytotoxic agents poses a risk of serious adverse events that can compromise patient well-being and patient outcomes. Trilaciclib represents a novel approach to protect against the side effects of cytotoxic therapy, but it also holds the potential to extend survival in certain cancer types, especially in combination with other novel anti-cancer interventions such as ADCs and checkpoint inhibitors—a benefit we are currently exploring in a variety of clinical trials with important readouts throughout 2023.”
